| Autor: |
Rajangam, Jayaraman, Palei, Narahari N., R., Prakash, Subramanam, Navaneetha Krishnan, P., Dharani Prasad, Ayyanna, Chakali, Aparna, S. |
| Předmět: |
|
| Zdroj: |
Pharmata; Jul2024, Vol. 4 Issue 3, p64-70, 7p |
| Abstrakt: |
Objective: The effect of Etoricoxib (ETOR) on the link between blood glucose and seizure prevention in chemo-convulsive rats was investigated in this study. Methods: Pentylenetetrazol (PTZ-105 mg/kg i.p.) at the CD97 dosage was administered to rats to cause seizures. ETOR (10 mg/kg p.o.) was administered for two weeks prior to seizure induction. On the 14th day, the animals were exposed to chemo convulsions, and the efficiency of ETOR in lowering clonus-type chemo convulsions (CC) as well as blood glucose levels were assessed. Morphometric analysis and chimney tests were performed to evaluate ETOR's neurotoxic profile. Actophotometer, rotarod, and hole board tests were employed for behavioral analysis. Results: When compared to control mice, pretreatment with ETOR (10 mg/kg p.o) resulted in a substantial delay in the onset of CC (P<0.05) and duration of CC (P<0.01). Acute ETOR treatment also considerably lowered blood glucose levels. The chimney test findings show that it has no effect on motor control and is not neurotoxic to the animals. Conclusion: Behavioral tests also demonstrated that, except for the diazepam-treated groups, no significant changes in muscle coordination, locomotion, or apprehensive behavior were detected in all experimental animals. Finally, the primary findings of this study showed that the PTZ group had considerably greater levels of hyperglycemia, which is reflected in the rat's early onset and longer duration of chemo-convulsions. However, ETOR medication reduced high blood glucose levels as well as the onset and duration of seizures, indicating ETOR's impact on blood glucose reduction and the relationship between blood glucose and seizure responses. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
